Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
Status:
Not yet recruiting
Trial end date:
2024-06-03
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice
daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).